Novonesis reports 8% sales growth in 2024, plans share buyback program for 2025

From GlobeNewswire: 2025-02-26 01:58:00

In 2024, Novonesis reported organic pro forma sales growth of 8% and an adjusted EBITDA margin of 36.1%. They launched 45 new innovations and announced a EUR 100m share buyback program for 2025. The outlook for 2025 includes a projected 5-8% sales growth and 37-38% EBITDA margin. Food & Health Biosolutions saw 7% growth, while Planetary Health Biosolutions grew by 9%. The company’s net debt/EBITDA ratio at the end of 2024 was 1.4x. CEO Ester Baiget expressed satisfaction with the performance and expects continued growth in 2025.

Pro forma sales for Novonesis in 2024 reached EUR 3,945.5 million, with organic growth at 8% and a 36.1% adjusted EBITDA margin. Food & Health Biosolutions had a 7% sales growth, while Planetary Health Biosolutions saw a 9% increase. The company’s 2025 outlook includes a projected 5-8% organic sales growth and a 37-38% EBITDA margin, with a stronger performance expected in the first half of the year. All figures are based on 2024 full-year data, and exclude certain impacts and acquisitions.



Read more at GlobeNewswire: 12M 2024 Company announcement